The semaglutide dose guide most people get wrong

The myth: higher doses work faster, so you should push to reach them quickly

This is the biggest misconception our prescribers encounter. People assume the starting dose is just a formality, a gate to pass through as fast as possible before the real treatment begins. In practice, rushing the schedule is one of the most reliable ways to end up in genuine discomfort.

Semaglutide slows how fast your stomach empties. At low doses, most people barely notice. Increase too quickly, and nausea, vomiting and fatigue can arrive sharply. The four-week minimum at each step isn't arbitrary caution; it's calibrated to let your gut adapt before the next increment. Your prescriber may hold you at a dose longer if side effects haven't settled, and that's correct clinical judgement, not a delay.

The full Wegovy treatment overview covers how the medicine works at a biological level, but the short version is: semaglutide acts on appetite-regulating receptors in the brain and slows gastric emptying. Both effects intensify as the dose rises, which is precisely why the titration exists. Patience with the schedule is part of the treatment.

The five-step Wegovy schedule in practice

The licensed UK titration pathway runs: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, with 2.4 mg as the standard maintenance dose. Most people reach maintenance around week 16, though your prescriber may adjust that timeline based on how you're tolerating each step. If you want a clear breakdown of what each phase involves, our wegovy dose guide walks through the schedule in full detail.

A practical check you can do in under a minute: before each new pen, look at the dose label and confirm it matches what your prescriber has documented for this stage of your treatment. It sounds obvious, but a mislabelled or wrong-strength pen from an unverified source is one of the documented risks highlighted by the MHRA. Confirming takes seconds and matters.

At 2.4 mg, the evidence base is substantial. The STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo) recorded around 15% average body-weight reduction. That's the figure the NICE appraisal of semaglutide (TA875) draws on when setting NHS eligibility criteria. Private prescribing follows the same clinical evidence but without the NHS's specialist-service requirements.

The 7.2 mg dose, approved by the MHRA in early 2026, is the maximum available and is indicated for adults with a BMI of 30 or above. Trial data at 7.2 mg reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's results significantly. It isn't a routine next step after 2.4 mg; your prescriber decides whether it's appropriate for you. For a closer look at the higher end of the range, questions about exceeding standard Wegovy doses are covered separately.

Side effects tend to follow the dose steps, here's what to watch for

The side-effect pattern with semaglutide is well-documented. Nausea is most common; vomiting, diarrhoea, constipation and indigestion are also frequently reported. These effects tend to peak in the first few days after each dose increase and ease as the body adjusts, typically within one to two weeks.

Fatigue and headache are reported less often but do occur, particularly early in treatment. Injection-site reactions are usually mild and transient. The NHS patient information for semaglutide on the NHS website lists these in full alongside guidance on when to seek medical advice.

Pancreatitis is an infrequent but serious risk across GLP-1 medicines: seek urgent help for severe, persistent stomach pain that spreads to the back, with or without vomiting. Gallbladder problems have also been reported. If you're losing weight rapidly, staying adequately hydrated is important, dehydration compounds the GI side effects and can put additional strain on the kidneys. If you have concerns at any point, the support team at nume is available seven days a week.

The question people often ask about missing a step or going back down a dose level is a clinical one. Your Patient Information Leaflet and your prescriber are the right sources for that guidance, and our wegovy dosage guide also covers common questions about adjustments in plain language.

Who the licensed schedule applies to, and what private prescribing looks like

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. These are the licensed parameters; a prescriber then assesses your full picture before confirming suitability.

On the NHS, NICE's TA875 recommendation limits Wegovy to a maximum of two years and requires access through specialist weight-management services, services with significant waiting lists in most areas. Private prescribing through a regulated pharmacy doesn't require a referral or a wait. At nume, a GPhC-registered prescriber reviews your consultation the same day, seven days a week, and if you're clinically suitable your treatment is dispatched the same day when you order before 12pm on a weekday.

The cost context for Wegovy in the UK is worth reading if price is part of your decision. And if you're weighing the injection against other formats or medicines, the treatment overview sets out the options clearly. When you're ready to find out whether the Wegovy schedule is right for you, check your eligibility with a free consultation, there's no obligation, and a real prescriber reviews every response.